Celldex Therapeutics, Inc. CLDX
30.65 USD -0.59 (-1.89%)
At closeNov 11, 2026, 6:10 AM EST
31.23 +0.58 +1.89%
Pre-market · Nov 11, 6:10 AM ET
30.52 Day range 31.71
22.10 52-week range 45.14
- YTD
- +12.85%
- 1 year
- +35.20%
News
marketbeat.com Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results Celldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria,…
benzinga.com Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68 Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.
benzinga.com Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61 Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.- benzinga.com Celldex Therapeutics Q3 EPS $(0.96) Beats $(1.02) Estimate Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.02) by 5.88 percent. This is a 4.95 percent increase over losses of…
globenewswire.com Celldex to Present at Upcoming Investor Conferences HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd…